Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02307240 · ClinicalTrials.gov registry record · Phase 1

Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors

A Phase 1 study of Solid Tumors and Triple Negative Breast Cancer, sponsored by Curis.

Completed
Registry status
Phase 1
Development phase
43
Enrollment target
4
Study locations

NCT02307240: Completed Phase 1 study of Solid Tumors and Triple Negative Breast Cancer, sponsored by Curis.

NCT02307240 is a Phase 1 study of Solid Tumors and Triple Negative Breast Cancer that has completed, run by Curis. The registered enrollment target is 43 participants, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (85% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02307240, a Phase 1 study of Solid Tumors and Triple Negative Breast Cancer, has completed, sponsored by Curis.

COMPLETED
Registry status
Phase 1
Development phase
43 participants
Enrollment target
4
Study locations

Study Summary

This is a Phase I, open-label, multi-center trial designed to evaluate the safety, tolerability and pharmacokinetics of CUDC-907 administered orally to subjects with advanced/relapsed solid tumors.

Conditions Studied

Solid Tumors Triple Negative Breast Cancer High-grade Serous Ovarian Cancer NUT Midline Carcinoma

Interventions

  • DRUG CUDC-907

Study Locations (4)

California

  • UCSF School of Medicine - San Francisco

Florida

  • Florida Cancer Specialists - Sarasota

Massachusetts

  • Dana-Farber Cancer Institute - Boston

Texas

  • The University of Texas MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 43 participants
Start Date 2014-11
Est. Completion 2019-05-31
Phase Phase 1
Curis

12 total trials

What the finished NCT02307240 record still lists

NCT02307240 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (85% lower).

The record links to 4 conditions, with Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which CUDC-907 is the first listed.

NCT02307240 reports a single indexed study location in California, Florida, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT02307240 about?

NCT02307240 is a clinical study titled "Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors". This is a Phase I, open-label, multi-center trial designed to evaluate the safety, tolerability and pharmacokinetics of CUDC-907 administered orally to subjects with advanced/relapsed solid tumors.

What is the current status of trial NCT02307240?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 43 participants. The study started on 2014-11. Estimated completion is 2019-05-31.

What conditions does trial NCT02307240 study?

This clinical trial studies the following conditions: Solid Tumors, Triple Negative Breast Cancer, High-grade Serous Ovarian Cancer, NUT Midline Carcinoma.

What interventions are being tested in trial NCT02307240?

The interventions under investigation include: CUDC-907 (DRUG).

Who is sponsoring clinical trial NCT02307240?

This trial is sponsored by Curis, which has 12 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02307240 being conducted?

This trial has 4 study locations across California, Florida, Massachusetts, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02307240's enrollment target sits among peer trials

43 91st of 125 higher than 34 of 125 other Solid Tumors trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03726359 · 43 participants · Phase 1

    Phase I Study of Fractionated Stereotactic Radiation Therapy

  • NCT03850418 · 43 participants · Phase 2

    Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant

  • NCT04144023 · 43 participants · Phase 1

    A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ

  • NCT04176718 · 43 participants · Phase 2

    Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT02307240, the US trial registry maintained by the National Library of Medicine. NCT02307240 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.